Scientists raise red flags over hidden risks of popular garden plant: 'Should serve as a bright yellow warning'
But new research has suggested that this trend could be fueling an environmental threat, according to The Conversation. Scientists warn that the species is spreading into the wild and disrupting native ecosystems — a development that "should serve as a bright yellow warning" that non-native fungi should be grown with great care, if at all.
What's happening?
The recent study found that golden oyster mushrooms, originally native to Asia, have become invasive in North American forests.
By collecting and analyzing fungal DNA from trees around Madison, Wisconsin, the researchers discovered that trees colonized by golden oysters housed only half as many fungal species as unaffected trees — sometimes even less.
According to the research, which was originally published in Cell's Current Biology journal, some native fungi, such as the mossy maze polypore, elm oyster, and the chemically rich Nemania serpens, were completely pushed out.
The sharp decline in fungal diversity is a strong indicator that golden oysters are outcompeting native fungi for critical resources, altering the delicate balance of forest life.
Why are invasive mushrooms concerning?
Fungi play an essential role in keeping ecosystems healthy for humans and other organisms. They break down dead organic material, recycle nutrients, form symbiotic relationships with plants, and help sequester carbon in the soil.
When an invasive species like the golden oyster mushroom takes hold, it can decimate native fungal communities that have evolved over centuries to support local forests, as The Conversation explained.
As the native fungi are pushed out, forests may become more vulnerable to disease, biodiversity loss, and nutrient imbalances. This is an even more concerning problem in regions already stressed by climate change and habitat destruction.
This disruption doesn't just affect trees and soil. Protecting native fungi and other species helps safeguard natural resources, food webs, and even the resilience of forest ecosystems against emerging threats.
Would you live in a house made of fungus?
Heck yes
No way
Maybe
Only if you paid me
Click your choice to see results and speak your mind.
What's being done about invasive mushrooms?
In The Conversation, study author Aishwarya Veerabahu recommended that mushroom growers and hobbyists avoid using golden oyster mushroom grow kits. Cultivating them indoors only and disposing of all substrate material responsibly was one suggested alternative to completely avoiding them. Commercial sellers can also include labeling to inform buyers about the species' invasive potential.
Those eager to grow mushrooms at home can try cultivating native fungi from their local area. Choosing native species supports biodiversity and helps maintain the unique ecological networks your region depends on.
Long-term solutions may include developing sporeless strains of golden oyster mushrooms or using biological controls, such as targeted mycoviruses. In the meantime, public awareness and responsible cultivation are vital to preventing further spread.
As golden oysters continue spreading in North America and begin showing up in forests in Europe, Africa, and beyond, Veerabahu expressed hope that the research encourages more thoughtful approaches to growing and managing mushrooms.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
2 hours ago
- CNET
Generative AI Gave MIT Scientists a New Tool to Fight Antibiotic-Resistant Bacteria
Antibiotic-resistant bacteria are dangerous because they already "know" what most antibiotics look like. Scientists at MIT have found a way to create something new: using generative AI to design two antibiotic compounds from scratch that can kill drug-resistant gonorrhea and MRSA in lab dishes and mice. Antibiotic resistance is one of the world's biggest public health threats yet new antibiotics have been scarce for decades. Traditional drug discovery methods rely on screening known chemical libraries -- a slow process with a limited pool of existing molecules to test. In contrast, MIT's AI system generated more than 36 million theoretical compounds, many with chemical structures never seen before, and zeroed in on two standouts. Both are unlike any antibiotic currently in use, offering a glimpse at how AI can move beyond speeding up research to imagine medicines that might have been impossible to find otherwise. "We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way," said Aarti Krishnan, MIT postdoc and one of the study's lead authors. "By venturing into underexplored areas of chemical space, our goal was to uncover novel mechanisms of action." Read also: Do You Really Learn When You Use AI? What MIT Researchers Found How the science was pulled off The MIT team bypassed the limitations of screening existing chemical libraries by asking AI to invent molecules from scratch, generating more than 36 million theoretical compounds, which were then narrowed down to a few to be tested against drug-resistant superbugs. This involved two AI-driven strategies: Fragment-based design: The AI began with a chemical fragment (labeled F1) that showed promise against gonorrhea. It produced millions of derivatives, ultimately refining a shortlist of about 1,000 candidates. Of the 80 chosen by researchers, NG1 emerged as a standout compound that successfully treated drug-resistant gonorrhea in cell cultures and a mouse. Unconstrained generation: The team let the AI roam freely, designing molecules on its own, aiming at MRSA. This produced more than 29 million candidates, which were filtered down to 90 compounds for synthesis. Twenty-two were produced, six performed well in lab tests and one in particular, DN1, proved able to eliminate MRSA skin infections in mice. NG1 and DN1 are structurally distinct from any currently known antibiotics and appear to destroy bacteria by disrupting their cell membranes. NG1 specifically targets LptA, a previously untapped bacterial protein involved in constructing the outer cell membrane. What's next for antibiotic research Phare Bio, a nonprofit in the Antibiotics-AI Project, is refining NG1 and DN1 to improve their drug properties, while researchers expand the AI platform to target other tough pathogens like Mycobacterium tuberculosis (the causative agent of tuberculosis) and Pseudomonas aeruginosa (a group of bacteria that often causes infections in health-care settings). The study, first published in the journal Cell, signals a hopeful turn in the global struggle against superbugs. However, these findings are early-stage. Initial tests and lab results are encouraging, but human safety and efficacy must be established through rigorous lab refinement and clinical trials, a process that could span several years. This effort builds on MIT's previous breakthroughs in AI-guided antibiotic development, including halicin, discovered in 2020 via deep learning, and abaucin, discovered in 2023 via a machine-learning algorithm. Read more: AI Essentials: 29 Ways to Make Gen AI Work for You, According to Our Experts
Yahoo
3 hours ago
- Yahoo
Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Precigen and Pfizer, as well as updates from the Institute for Clinical and Economic Review, Superluminal Medicines and Generation Bio that you may have missed. The Food and Drug Administration granted full approval to a first-of-its-kind treatment for recurrent respiratory papillomatosis, a rare and potentially life-threatening condition caused by persistent HPV infections. Thursday's clearance of Precigen's Papzimeos, an immunotherapy that helps clear HPV-infected cells, was based on study results showing a little more than half of drug recipients didn't need surgery within a year of therapy. Center for Biologics Evaluation and Research director Vinay Prasad, who rejoined the FDA this week, described the approval as proof 'randomized trials are not always needed to approve medical products.' That statement should be 'reassuring' to biotech investors concerned about stricter regulatory standards under Prasad, wrote Cantor Fitzgerald analyst Jennifer Kim. Precigen shares rose higher Friday on the news. — Ben Fidler An experimental Pfizer drug for sickle cell disease failed to meet its goal in a Phase 3 study, the company said Friday. Testing showed that treatment with inclacumab, a drug Pfizer acquired via its 2022 buyout of Global Blood Therapeutics, failed to significantly reduce versus placebo the pain crises people with sickle cell often experience. Pfizer said it would share analyses of the data with the scientific and patient community in 'due course.' Last year, the company pulled from market another sickle cell drug, Oxbryta, that it gained from Global Blood, citing safety concerns. The company plans to provide updates on Oxbryta and a third Global Blood drug, the experimental osivelotor, when they become available. — Ned Pagliarulo Eli Lilly will collaborate with biotechnology startup Superluminal Medicines to develop new drugs for cardiometabolic diseases and obesity. Through the alliance, the two intend to discover and advance small molecule medicines aimed at undisclosed G protein-coupled receptor, or GPCR, targets 'relevant' to those conditions. Lilly will receive exclusive rights to the compounds emerging from the deal, while Superluminal could get up to $1.3 billion in total payouts, including an unspecified upfront payment as well as an equity investment, the companies said Thursday. — Ben Fidler Autolus Therapeutics is delaying launching its leukemia cell therapy Aucatzyl in Europe following approval there as the company 'evaluates potential pricing and feasibility of market entry opportunities' in some countries. Launch in Germany is on hold and Autolus 'does not anticipate any EU sales of Aucatzyl in 2025 and 2026,' the company said in its second quarter earnings report. In the U.K., where Aucatzyl has also been approved, a government cost-effectiveness monitor has initially decided not to pay for it. Autolus said it 'will continue to work towards a pathway for patient access to therapy in the U.K.' Approved by the Food and Drug Administration in November 2024, Aucatzyl earned just shy of $30 million in sales in the first six months of 2025, all from the U.S. — Jonathan Gardner Generation Bio revealed preclinical results suggesting a delivery technology it's developing can effectively send nucleic acid payloads into T cells. But the company also said this week that it may not be able to raise the funds to prove that approach works in humans and, as a result, began a strategic review that could end in a sale or merger. Generation will lay off roughly 90% of its workforce, including all of its research and development staff, by the end of October. Company shares climbed 60%, though they've lost much of their value since the company's initial public offering in 2020. — Ben Fidler Recommended Reading Eli Lilly's Julie Gilmore on finding up-and-coming companies and backing small biotechs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
3 hours ago
- Gizmodo
Toothpaste Made From Hair Works Better Than Fluoride, Scientists Say
Looking for an effective, sustainable toothpaste? It might be on top of your head. Scientists have discovered that keratin, a protein found in hair, skin, and wool, can repair tooth enamel and stop tooth decay. It might also protect teeth even better than conventional fluoride-based toothpastes, stopping tooth decay in its tracks, according to a new study. When keratin comes into contact with saliva, it forms a protective coating that mimics natural enamel, the study shows. Not only can it shield teeth from further damage, but it may also help repair enamel—something traditional toothpastes can't do. The findings are published in Advanced Healthcare Materials. 'Keratin offers a transformative alternative to current dental treatments. Not only is it sustainably sourced from biological waste materials like hair and skin, it also eliminates the need for traditional plastic resins, commonly used in restorative dentistry, which are toxic and less durable,' Sara Gamea, a graduate student at King's College London and first author of the study, said in a statement. Tooth enamel wears away with age, leading to tooth sensitivity and eventually a need for dentures. This process is hastened by acidic foods and poor oral hygiene. And once enamel is gone, it's gone. Fluoride toothpaste can slow this process but not stop it. What can? Keratin, apparently. The protein forms a dense crystal-like scaffold that mimics the structure, color, and function of actual enamel, the new study found. Over time, the scaffold continues to attract calcium and phosphate ions, leading to the growth of an enamel-like coating on teeth. That means keratin-based toothpaste could potentially repair lost enamel and seal exposed nerves—reversing the symptoms of enamel erosion. The study authors used keratin extracted from wool in their study but said it could also be extracted from other sources, including human hair. This is a huge step for regenerative dentistry, the researchers say. It's also good for the environment, providing a biodegradable alternative to conventional toothpastes. And happily, consumers might not have to wait long to purchase a keratin-based toothpaste; the researchers say it could hit the market in the next two to three years. 'We are entering an exciting era where biotechnology allows us to not just treat symptoms but restore biological function using the body's own materials. With further development and the right industry partnerships, we may soon be growing stronger, healthier smiles from something as simple as a haircut,' Sherif Elsharkawy, the study's lead author and consultant in prosthodontics at King's College London, said in a statement.
